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Abstract 
Introduction 
The objective of this study was to describe the prevalence of and factors associated with metabolic syndrome among 
adult New York City residents. 
Methods 
The 2004 New York City Health and Nutrition Examination Survey was a population-based, cross-sectional study of 
noninstitutionalized New York City residents aged 20 years or older. We examined the prevalence of metabolic 
syndrome and its components as defined by the National Cholesterol Education Program’s Adult Treatment Panel III 
revised guidelines, according to demographic subgroups and comorbid diagnoses in a probability sample of 1,263 
participants. We conducted bivariable and multivariable analyses to identify factors associated with metabolic 
syndrome. 
Results 
The age-adjusted prevalence of metabolic syndrome was 26.7% (95% confidence interval, 23.7%-29.8%). Prevalence 
was highest among Hispanics (33.9%) and lowest among whites (21.8%). Prevalence increased with age and body mass 
index and was higher among women (30.1%) than among men (22.9%). More than half (55.4%) of women and 33.0% 
of men with metabolic syndrome had only 3 metabolic abnormalities, 1 of which was abdominal obesity. The most 
common combination of metabolic abnormalities was abdominal obesity, elevated fasting blood glucose, and elevated 
blood pressure. Adjusting for other factors, higher body mass index, Asian race, and current smoking were positively 
associated with metabolic syndrome; alcohol use was inversely associated with metabolic syndrome among women but 
increased the likelihood of metabolic syndrome among men. 
Conclusion 
Metabolic syndrome is pervasive among New York City adults, particularly women, and is associated with modifiable 
factors. These results identify population subgroups that could be targeted for prevention and provide a benchmark for 
assessing such interventions. 
Introduction 
Several risk factors for cardiovascular disease (CVD), including abdominal obesity, elevated fasting blood glucose, 
elevated triglycerides, elevated blood pressure, and low high-density lipoprotein (HDL) cholesterol, tend to cluster in 
individuals (1). The simultaneous presence of 3 or more of these has been termed the metabolic syndrome (MetS). 
Even when these metabolic abnormalities are present at predisease levels, MetS is associated with an elevated CVD 
risk and with cardiovascular and all-cause mortality (2,3). 
Much remains unknown about MetS, including its causes. Whether or not MetS confers greater CVD risk than the sum 
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consensus on screening for MetS or on treatment of people with MetS who do not have diabetes, hypertension, or 
dyslipidemia. Nonetheless, people with MetS are at higher risk of CVD and may benefit from long-term follow-up and 
aggressive preventive care (5). 
In addition to its potential to identify high-risk people, MetS is a useful indicator of population-level CVD risk. The 
National Health and Nutrition Examination Survey (NHANES) 2003-2006 found that 34% of US adults have MetS (6). 
MetS prevalence varies among racial and ethnic groups (7); other factors associated with MetS include older age, lower 
socioeconomic status, and smoking (7,8). 
Whether NHANES reflects the epidemiology of MetS in settings with marked socioeconomic and racial/ethnic 
diversity is unknown. One study describing MetS among New York City adults who did not have diabetes focused on 
differences between Asians and whites (9). The objective of our study was to describe the prevalence of and factors 
associated with MetS among New York City adults among all racial/ethnic groups. We also evaluated the prevalence of 
MetS among participants with comorbid conditions such as diabetes and hypertension. 
Methods 
The New York City (NYC) Health and Nutrition Examination Survey (NYC HANES) 2004 is described elsewhere (10). 
It was a population-based, cross-sectional survey of noninstitutionalized adult NYC residents. Participants gave 
informed consent for participation. The NYC Department of Health and Mental Hygiene (DOHMH) institutional 
review board approved the study. 
Eligible participants were selected for the survey by using a 3-stage cluster sampling design. Between June 2 and 
December 19, 2004, participants completed a face-to-face, computer-assisted interview, physical examination, and 
biologic specimen collection, including fasting blood glucose measurements. Of 3,047 eligible NYC residents, 1,999 
completed the interview and at least 1 examination component (overall response rate, 55%). We excluded pregnant 
women (n = 12) and people who did not complete either (or both) examination component (n = 649). Of 1,338 
nonpregnant NYC HANES participants with both examination components, we then excluded people (n = 75) who 
lacked valid data on fasting blood glucose, triglycerides, HDL cholesterol, waist circumference, blood pressure, and 
prescription medication use for diabetes or hypertension. We thus included 1,263 of 1,338 (94%) participants with 
complete data in this analysis. 
MetS criteria 
We used the MetS definition used for NHANES 2003-2006 (6). This definition incorporates medical treatment for 
hypertension and elevated fasting blood glucose (5) but is otherwise identical to the Third Report of the National 
Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP III) MetS definition (11). We thus defined MetS 
as the presence of 3 or more of the following: abdominal obesity (waist circumference ≥88 cm in women or ≥102 cm in 
men); low HDL cholesterol (<50 mg/dL in women or <40 mg/dL in men); elevated triglycerides (≥150 mg/dL); 
elevated fasting blood glucose (≥100 mg/dL or use of oral hypoglycemic medication or insulin or both); or elevated 
blood pressure (at least 1 of the following: systolic ≥130 mmHg, diastolic ≥85 mmHg, or use of antihypertensive 
medication). We did not collect data on medication use for elevated triglycerides or low HDL cholesterol. 
Variable definitions 
We recategorized self-reported race and Hispanic ethnicity as non-Hispanic white, non-Hispanic black, Hispanic, or 
non-Hispanic Asian; we excluded 17 people reporting “other race” from analyses on race/ethnicity. We defined people 
born in the United States or US territories as US-born. We defined educational levels as less than a high school degree, 
completion of high school or general educational development (GED) certificate, or more than a high school degree or 
GED. We considered people reporting any form of private health insurance to have private insurance; people reporting 
no private insurance but Medicare, Medicaid, or any other government coverage to have government insurance; and 
people reporting no health insurance to be uninsured. We categorized people who reported having no routine place of 
health care or receiving care at emergency departments as lacking a routine place of care. We defined smoking as 
current (having smoked ≥100 cigarettes in a lifetime and currently smoking every day or on some days), past (having 
smoked ≥100 cigarettes in a lifetime but not currently smoking), or never (having smoked <100 cigarettes in one's 
lifetime). We defined alcohol use as heavy (average of >2 drinks per day for men and >1 drink per day for women in the 
past year), moderate (less frequent alcohol use in the past year), or low/none (no drinking reported in the past year). 
We defined clinical hypertension as the presence of at least 1 of the following: systolic measurement of 140 mmHg or 
higher, diastolic measurement of 90 mmHg or higher, or use of antihypertensive medication; diabetes as the presence 
of at least 1 of the following: a fasting blood glucose of more than 125 mg/dL, use of oral hypoglycemic medication or 
insulin, or a self-reported history of clinician-diagnosed diabetes; and high LDL cholesterol according to ATP III 
guidelines (12). We calculated body mass index (BMI, kg/m ) by using measured height and weight; we defined 
underweight as a BMI less than 18.5, normal weight as a BMI of 18.5 to 24.9, overweight as a BMI of 25.0 to 29.9, and 
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underweight and normal weight into a single category for multivariable analyses. 
Statistical methods 
Unless otherwise noted, prevalence estimates were age-adjusted to the 2000 US standard population. Among people 
with MetS stratified by sex, we examined metabolic abnormalities that resulted in the classification of MetS. We 
ranked various combinations of metabolic abnormalities from the most to the least common to examine their relative 
importance and the extent to which metabolic abnormalities differed by sex. We examined the prevalence of MetS 
among participants with and without diabetes, hypertension, high LDL cholesterol, and obesity. 
We used the t test to determine significant differences in prevalence rates for categorical variables and calculated 
relative standard errors (RSEs) and 95% confidence intervals (CIs) for percentages. We considered P values of less 
than .05 to be statistically significant and estimates with an RSE of 30% or more or a denominator of 50 people or 
fewer to be unreliable. We used SAS version 9.1 (SAS Institute, Cary, North Carolina) with SUDAAN version 10 
(Research Triangle Institute, Research Triangle Park, North Carolina) to account for the complex survey design and 
incorporated sample weights adjusted for differential selection probabilities and survey nonresponse to produce 
estimates representative of the NYC population. 
We constructed multiple logistic regression models to identify factors independently associated with MetS. We entered 
each variable with a P value of .20 or less for the Wald χ  test in bivariable analysis into the model individually and 
retained characteristics associated with MetS with a P value of less than .05 in final models. On the basis of sex 
differences identified in bivariable analysis, we tested interactions between sex and race/ethnicity, smoking status, 
alcohol use, and BMI, and found a significant interaction between sex and alcohol use. To further explore this 
interaction, we examined median values for key metabolic measurements according to level of alcohol use separately 
for men and women. We calculated adjusted odds ratios (AORs) and 95% CIs and adjusted prevalence estimates by 
using predicted marginals. We assessed multicollinearity in the final model; the highest level of correlation among 
covariates was less than 0.20. 
Results 
The final sample was 53.5% female, 39.2% white, 26.5% Hispanic, 23.3% black, and 11.0% Asian. Nearly half of 
participants (48.3%) were born outside the United States. Although most (54.1%) had completed more than a high 
school education, 39.1% had an annual family income of less than $25,000. More than half of the population was 
overweight (35.4%) or obese (25.7%). People with incomplete data did not differ from people with complete data in age 
distribution, sex, race/ethnicity, or education, but those with incomplete data were more likely to have a family income 
of less than $25,000 and to be overweight or obese. 
Prevalence of metabolic abnormalities 
Among women, the most prevalent metabolic abnormality was abdominal obesity (64.3%) (Table 1). Elevated fasting 
blood glucose was the most prevalent abnormality among men (43.1%). Low HDL levels were more common among 
women than among men (women, 30.9% vs men, 24.2%; t = 2.51, P = .01). Only one-fourth of participants had no 
metabolic abnormalities, whereas nearly half had 1 or 2 abnormalities. 
Prevalence of metabolic syndrome 
The overall age-adjusted prevalence of metabolic syndrome among NYC adults was 26.7% and was higher among 
women than among men (women, 30.1% vs men, 22.9%; t = 2.68, P = .008) (Table 2). Overall, Hispanics had a higher 
prevalence of MetS than whites (Hispanic, 33.9% vs white, 21.8%; t = 3.32, P = .001). 
Certain behavioral factors were associated with MetS prevalence. The prevalence of MetS was higher among current 
smokers (33.9%) than among never-smokers (25.2%) (t = 2.48, P = .01). Prevalence was higher among women with 
low or no alcohol use (38.1%) than among women who drank moderately (26.1%) (t = −2.86, P = .005) or heavily 
(12.0%) (t = −4.49, P < .001). In contrast, prevalence was higher among men with heavy alcohol use (36.6%) than 
among men with low or no alcohol use (21.8%), although this difference was not significant (t = 1.70, P = .06). MetS 
prevalence increased steadily with BMI; no underweight participants had MetS. 
Among both women and men with MetS, the most common combination of metabolic abnormalities was abdominal 
obesity, elevated fasting blood glucose, and elevated blood pressure (16.6% of men with MetS, 21.5% of women with 
MetS). More than half of women (55.4%) and 33.0% of men with MetS had only 3 metabolic abnormalities, 1 of which 
was abdominal obesity. 
Comorbid diagnoses 
Among participants who did not have diabetes, hypertension, or high LDL cholesterol and were not obese, 7.1% had 
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MetS (Figure 1). Women with hypertension (77.0%) were more likely to have MetS compared with men with 
hypertension (41.2%) (t = 4.07, P < .001), and women with high LDL cholesterol (56.3%) were more likely to have 
MetS compared with men with high LDL cholesterol (40.0%) (t = 2.19, P = .03). 
 
Figure 1. Age-adjusted prevalence of metabolic syndrome according to comorbid diagnosis, 2004 New York City 
Health and Nutrition Examination Survey. Error bars represent 95% confidence intervals. Abbreviations: LDL, low-
density lipoprotein. [A tabular version of this figure is also available.] 
Multiple logistic regression models 
In the final model, BMI and age remained positively associated with MetS (Figure 2). Prevalence was higher among 
current smokers than among never-smokers (AOR, 2.6; 95% CI, 1.8-3.8) and higher among Asians than among whites 
(AOR 2.4, 95% CI 1.4-4.1). Although prevalence of MetS was higher among men reporting heavy alcohol use compared 
with men reporting low or no alcohol use (AOR 2.8, 95% CI 1.1-7.6), it was lower among women who reported heavy or 
moderate alcohol use than among women who reported low or no alcohol use (AOR 0.2, 95% CI 0.1-0.6 and AOR 0.5, 
95% CI 0.3-0.9, respectively) (Figure 3). 
 
Figure 2. Adjusted prevalence (predicted marginals) of metabolic syndrome by race/ethnicity, smoking status, age, 
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and body mass index (BMI), 2004 New York City Health and Nutrition Examination Survey. BMI (kg/m ) categories 
were defined as underweight (low), <18.5; normal, 18.5-24.9; overweight, 25.0-29.9; and obese, ≥30. Each estimate is 
adjusted for sex, alcohol use, the interaction between sex and alcohol use, and all other variables in figure. Error bars 
represent 95% confidence intervals. [A tabular version of this figure is also available.] 
 
Figure 3. Adjusted prevalence (predicted marginals) of metabolic syndrome by sex and level of alcohol use, 2004 New 
York City Health and Nutrition Examination Survey. Alcohol use was defined as heavy (>2 drinks/day during the past 
year for men or >1 drink/day for women); moderate (less frequent use); or low/none (no drinking in the past year). 
Each estimate is adjusted for body mass index, age, smoking, and race/ethnicity. Error bars represent 95% confidence 
intervals. [A tabular version of this figure is also available.] 
Exploration of the relationship between alcohol use and sex 
In both sexes, median waist circumference was larger in participants reporting low or no alcohol use than in 
participants reporting moderate or heavy use; the difference was more pronounced among women than men (Table 3). 
Median triglycerides, HDL cholesterol, and fasting blood glucose levels were better among women reporting heavy 
alcohol use than among women reporting low or no alcohol use. Among men, however, the lowest triglyceride levels 
were observed in men reporting moderate alcohol use. No clear patterns emerged for other metabolic measurements. 
Discussion 
MetS affects more than one-fourth of NYC adults, accounting for more than 1.5 million people at greater risk for CVD-
related morbidity and mortality. Among people with MetS, the most common combination of syndrome components 
(abdominal obesity, elevated fasting blood glucose, and elevated blood pressure) may be associated with a particularly 
high risk of CVD (13). As in previous studies (7,8,14), we observed a steady increase in MetS prevalence with age and 
with BMI, suggesting that the scope of this problem is likely to grow as NYC’s population ages and if obesity becomes 
more prevalent. Our finding that most NYC adults without MetS have 1 or more metabolic abnormalities related to the 
syndrome is further evidence of the widespread risk of developing MetS. 
In keeping with previous reports of lower rates of hypertension, hypercholesterolemia, and obesity in NYC than in the 
United States overall (15), the age-adjusted prevalence of MetS in NYC HANES 2004 (26.7%) was lower than the 
national prevalence (34.0%) observed in NHANES 2003-2006 (6). Except for low HDL cholesterol (NYC, 27.8% vs 
national, 24.7%), the prevalence of each MetS abnormality was lower in the NYC population than in the national 
population (abdominal obesity, 47.0% vs 52.8%; elevated triglycerides, 22.5% vs 31.2%; elevated blood pressure, 31.3% 
vs 39.5%; and elevated fasting blood glucose, 35.7% vs 38.6%). Among women, except for abdominal obesity (NYC, 
64.3% vs national, 60.7%), the prevalence of each MetS abnormality was also lower among NYC populations than in 
the national sample: elevated triglycerides (21.0% vs 26.5%), elevated blood pressure (30.4% vs 35.2%), and elevated 
fasting blood glucose (24.9% vs 31.3%) (6). Differences between men in the 2 samples were more pronounced: 
abdominal obesity (26.8% vs 44.8%), elevated triglycerides (24.5% vs 35.6%), elevated blood pressure (33.0% vs 
43.4%), and elevated fasting blood glucose (43.1% vs 45.8%) (6). 
The prevalence of MetS was 7.2 percentage points higher among women than among men in our study. Although 
recent NHANES studies did not find a difference between sexes, the NHANES 1988-1994 and NHANES 1999-2000 
found a marked increase in prevalence among women, driven primarily by increases in blood pressure, waist 
circumference, and triglyceride levels (14). We found that abdominal obesity was common among women in the 
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compared with 33.0% of men. As recommendations for prevention and treatment of MetS are developed, a special 
focus on preventing abdominal obesity among NYC women may be warranted. 
We also observed differences in the relationship between alcohol use and MetS between sexes; level of alcohol use was 
inversely associated with MetS among women but increased the likelihood of MetS among men. Differences between 
sexes were also identified in the general NYC HANES population when we examined individual metabolic measures 
according to level of alcohol use. These data contrast with NHANES III data, which showed both an inverse 
relationship between level of alcohol use and MetS risk for both sexes (16) and a protective effect among women only 
(7). Other studies have also presented conflicting results on whether alcohol use has a protective or detrimental effect 
on MetS risk (17,18). These discrepancies may have resulted because of differences in how the studies defined alcohol 
use. Alternatively, because alcohol use has a positive impact on certain MetS components (19) but a variable effect on 
others (16), the relationship between alcohol use and MetS may differ according to the metabolic risk profile of the 
group being studied. Our results may be due to confounders we could not control. Regardless, additional studies 
adequately powered to elucidate the complex relationship between sex, alcohol use, and the components of MetS are 
needed. 
The diversity of our sample enabled us to examine MetS among Asians, which has not been examined nationally. The 
age-adjusted MetS prevalence among Asians in NYC (9) was similar to the prevalence among whites, but Asians had a 
higher prevalence of MetS after adjustment for other factors. Other studies have reported higher rates of diabetes and 
cardiovascular disease among Asians compared with whites (20,21). These data suggest an opportunity for targeted 
prevention efforts, of particular importance for other areas with large Asian American communities. 
Despite a close link between obesity and MetS, the prevalence of MetS was not negligible (6.5%) among normal-weight 
participants. Some studies have suggested that such people are already “metabolically obese” and may be susceptible to 
the negative effects of future weight gain (7,22) and have thus advocated aggressive dietary and exercise interventions 
(22). No guidelines exist for identifying and treating MetS in normal-weight people, but if this group is overlooked, so 
too would be their elevated risk of CVD. 
Our study had several limitations, including the small sample size, which prevented extensive examination of risk 
factors for MetS among demographic subgroups. We may have underestimated MetS prevalence because we excluded 
from analysis people with incomplete data; these people were more likely to be low-income or overweight. We did not 
assess associations between MetS and dietary and exercise patterns because NYC HANES gathered limited data on 
these topics. Finally, that the ATP III definition of MetS may not have uniform validity among age, sex, and 
racial/ethnic groups (5,7) is of particular relevance in diverse settings such as NYC. Nonetheless, the definition we 
chose has been used extensively, enabling comparisons among studies. 
Pending the development of recommendations for MetS screening and management, clinicians may wish to consider 
screening high-risk groups to help motivate people to pursue lifestyle changes that can mitigate or reverse MetS, 
including weight loss and increased physical activity (5). In particular, an opportunity exists for CVD risk modification 
among New Yorkers with MetS but without comorbid conditions and among New Yorkers with MetS who smoke. 
Detection of MetS and integration of MetS screening into routine practice may improve as electronic medical records 
become more widely available (23). 
Meanwhile, the widespread prevalence of MetS and its components suggests that population-level interventions are 
needed to address CVD risk. NYC has already taken several steps, including initiatives to encourage calorie labeling in 
chain restaurants, decrease levels of sodium in foods, eliminate use of trans fats in food establishments, increase the 
availability of fresh produce, and create an environment conducive to physical activity. Our findings may enable 
further tailoring of broad-scale prevention policies to the NYC population and will provide a benchmark by which such 
efforts may be measured. 
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 Abdominal obesity is defined as waist circumference ≥102 cm in men or ≥88 cm in women. 
 Significant difference (by t- test) between men and women. We conducted comparisons between men and women only for 
specific metabolic abnormalities, not for number of metabolic abnormalities. 
 Elevated triglyceride level is defined as a fasting triglyceride level ≥150 mg/dL. 
 Low HDL is defined as <40 mg/dL in men or <50 mg/dL in women. 
 Elevated blood pressure is defined as systolic ≥130 mmHg and/or diastolic ≥85 mmHg and/or use of medications for 
hypertension at time of survey. 
 Elevated blood glucose is defined as fasting glucose ≥100 mg/dL or use of insulin or oral hypoglycemic medication or both 
at time of survey. 
  
Table 2. Age-Adjusted Prevalence of Metabolic Syndrome Among New York 
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Prevalence or number
Total, % (95% CI) 
(n = 1,263)
Men, % (95% CI) 
(n = 539)
Women, % (95% CI) 
(n = 724)
Prevalence of abnormality
Abdominal obesity 47.0 (43.9-50.2) 26.8 (22.7-31.4) 64.3 (60.5-67.9)
Elevated triglyceride level 22.5 (19.8-25.5) 24.5 (20.7-28.8) 21.0 (17.5-25.0)
Low HDL cholesterol level 27.8 (24.8-31.0) 24.2 (20.5-28.3) 30.9 (26.8-35.2)
Elevated blood pressure 31.3 (28.7-34.0) 33.0 (29.2-37.1) 30.4 (27.5-33.6)
Elevated fasting blood glucose 35.7 (32.7-38.8) 43.1 (38.3-48.1) 29.4 (25.7-33.4)
Number of metabolic abnormalities
0 24.7 (22.4-27.2) 27.1 (24.0-30.4) 22.6 (19.7-25.7)
1 27.7 (25.1-30.6) 29.1 (24.7-33.8) 26.4 (23.2-29.9)
2 20.9 (18.3-23.7) 20.9 (17.3-25.0) 20.9 (17.6-24.8)
3 16.0 (13.6-18.7) 14.0 (10.9-17.7) 17.8 (14.6-21.6)
4 6.5 (5.1-8.2) 5.9 (4.1-8.5) 7.0 (5.2-9.4)
5 4.1 (2.9-5.9) 3.0 (1.7-5.4) 5.2 (3.4-8.0)
Characteristic
Total 
(n = 1,263)
Men 
(n = 539)
Women 
(n = 724)
No. % (95% CI) No. % (95% CI) No. % (95% CI)
Total 1,263 26.7 (23.7-29.8) 539 22.9 (19.1-27.2) 724 30.1 (26.3-34.1)
a,b
c
d
e
b,f
a
b
c
d
e
f
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20-29 [Reference] 325 7.3 (4.9-10.7) 150 8.4 (4.7-14.5) 175 6.3 (3.7-10.5)
30-39 301 18.4 (14.1-23.6) 128 19.4 (13.1-27.7) 173 17.5 (12.2-24.5)
40-49 288 21.0 (16.8-25.8) 113 18.0 (12.1-26.0) 175 23.3 (17.6-30.1)
50-59 194 34.7 (27.7-42.4) 73 26.2 (16.8-38.3) 121 40.6 (31.7-50.2)
≥60 155 49.2 (39.6-58.9) 75 40.2 (28.1-53.7) 80 58.8 (45.5-71.0)
Race/ethnicity
White [Reference] 366 21.8 (17.3-27.1) 175 20.1 (15.0-26.5) 191 23.5 (17.2-31.4)
Black 272 28.5 (23.5-34.0) 108 24.0 (15.8-34.6) 164 33.4 (26.9-40.6)
Hispanic 452 33.9 (28.5-39.8) 177 27.4 (20.3-35.9) 275 38.2 (31.9-44.8)
Asian 156 23.0 (15.9-32.0) 72 23.6 (14.2-36.6) 84 22.4 (13.2-35.4)
Education
<HS degree/GED 369 35.3 (30.1-40.8) 150 31.0 (23.7-39.3) 219 38.4 (31.6-45.7)
HS degree/GED 245 26.3 (20.0-33.7) 113 19.4 (11.3-31.2) 132 33.1 (24.9-42.4)
>HS degree/GED [Reference] 647 22.3 (18.6-26.5) 274 20.4 (15.7-26.0) 373 25.1 (20.2-30.8)
Country of birth
United States [Reference] 614 27.1 (23.2-31.4) 260 24.1 (19.0-30.1) 354 29.4 (24.1-35.4)
Other 648 26.1 (22.4-30.1) 278 20.5 (15.6-26.6) 370 31.4 (26.9-36.3)
Income, $
<25,000 507 28.2 (24.1-32.6) 195 21.5 (16.1-28.2) 312 32.8 (27.3-38.9)
25,000-49,999 308 26.5 (20.7-33.3) 142 24.2 (16.8-33.6) 166 28.7 (21.1-37.7)
≥50,000 [Reference] 398 24.5 (19.3-30.5) 187 22.6 (16.2-30.6) 211 26.6 (19.5-35.2)
Insurance coverage
Private [Reference] 596 24.5 (20.6-28.9) 257 21.6 (16.6-27.7) 339 27.3 (22.0-33.4)
Government 330 32.6 (27.3-38.) 109 25.6 (17.7-35.4) 221 38.0 (31.5-44.9)
Uninsured 332 24.4 (18.5-31.4) 169 24.1 (16.4-33.9) 163 24.8 (16.4-35.6)
Routine source of care
Present [Reference] 874 27.3 (23.9-31.0) 342 22.8 (18.3-28.1) 532 31.0 (26.8-35.5)
Absent 388 25.1 (18.5-33.0) 197 22.3 (13.9-33.8) 191 28.7 (19.9-39.6)
Smoking
Never [Reference] 726 25.2 (21.6-29.2) 269 19.2 (14.0-25.6) 457 29.6 (25.7-34.0)
Current 319 33.9 (28.5-39.9) 160 28.6 (20.6-38.1) 159 39.6 (31.0-49.0)
Former 218 23.4 (18.1-29.7) 110 23.8 (17.1-32.0) 108 23.1 (15.8-32.5)
Alcohol use
Heavy 99 27.5 (18.4-39.0) 49 36.6 (24.9-50.0) 50 12.0 (5.2-25.4)
Moderate 775 23.7 (20.0-27.8) 378 21.9 (17.3-27.3) 397 26.1 (20.8-32.2)
Low or none [Reference] 384 32.4 (27.5-37.8) 110 21.8 (14.5-31.2) 274 38.1 (32.5-44.0)
Body mass index, kg/m
Underweight (<18.5) 28 0 10 0 18 0
Normal weight (18.5-24.9) [Reference] 464 6.5 (4.1-10.3) 182 6.3 (3.4-11.6) 282 6.8 (3.6-12.5)
Overweight (25-30)
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Abbreviations: CI, confidence interval; GED, general educational development; HS, high school; NA, not applicable. 
 P value < .001. Comparisons were made by t test to the reference group in each category. 
 P value < .05. Comparisons were made by t test to the reference group in each category. 
 P value < .01. Comparisons were made by t test to the reference group in each category. 
 Totals do not equal to 1,263 because of missing data. 
 Relative standard error was 30% or more or denominator was 50 or fewer (or both). We considered such estimates to be 
unreliable. 
  
Table 3. Metabolic Measurements According to Alcohol Use and Sex Among 
New York City Adults Aged 20 years or Older, 2004 New York City Health 
and Nutrition Examination Survey 
Abbreviations: CI, confidence interval; HDL, high-density lipoprotein. 
 Alcohol use defined as heavy (>2 drinks/d during the past year for men or >1 drink/d for women); moderate (less 
frequent use); or low/none (no drinking in the past year). 
 Denominator was 50 or fewer for both men and women who reported heavy alcohol use. We considered such estimates to 
be unreliable. 
432 28.2 (23.8-33.2) 212 20.1 (14.7-26.9) 220 38.7 (33.5-44.1)
Obese (≥30) 316 49.7 (44.0-55.5) 122 47.4 (38.7-56.2) 194 50.7 (42.6-58.7)
Menopausal status
Premenopausal [Reference] NA NA NA NA NA NA 530 29.8 (22.1-38.9)
Postmenopausal NA NA NA NA NA NA 183 26.7 (22.2-31.7)
Metabolic Measure Alcohol Use
Men, 
Median (95% CI)
Women, 
Median (95% CI)
Waist circumference, cm
Heavy 91.6 (88.1-96.4) 87.0 (83.0-93.0)
Moderate 94.1 (92.6-95.9) 91.5 (90.1-94.2)
Low/none 95.5 (93.5-98.6) 95.5 (93.4-98.6)
Triglycerides, mg/dL
Heavy 123 (104-169) 84 (72-96)
Moderate 106 (100-115) 91 (84-96)
Low/none 117 (110-124) 110 (93-121)
HDL cholesterol, mg/dL
Heavy 46 (42-53) 65 (59-70)
Moderate 47 (45-49) 58 (55-60)
Low/none 43 (41-45) 53 (51-55)
Systolic blood pressure, mmHg
Heavy 117 (112-122) 106 (104-112)
Moderate 116 (113-118) 107 (105-109)
Low/none 118 (115-121) 112 (110-115)
Diastolic blood pressure, mmHg
Heavy 73 (71-76) 68 (66-72)
Moderate 73 (71-74) 68 (67-69)
Low/none 73 (70-76) 68 (66-70)
Fasting blood glucose, mg/dL
Heavy 100 (92-111) 88 (86-93)
Moderate 96 (95-98) 92 (90-93)
Low/none 99 (94-103) 95 (94-97)
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